CY2208B1 - Delta-amino-gamma-hydroxy-omega-aryl alkanoic acidamides with enzyme especially renin inhibiting ac tivities - Google Patents
Delta-amino-gamma-hydroxy-omega-aryl alkanoic acidamides with enzyme especially renin inhibiting ac tivitiesInfo
- Publication number
- CY2208B1 CY2208B1 CY0000064A CY0000064A CY2208B1 CY 2208 B1 CY2208 B1 CY 2208B1 CY 0000064 A CY0000064 A CY 0000064A CY 0000064 A CY0000064 A CY 0000064A CY 2208 B1 CY2208 B1 CY 2208B1
- Authority
- CY
- Cyprus
- Prior art keywords
- opt
- substd
- alkylene
- cooh
- mono
- Prior art date
Links
- 150000001408 amides Chemical class 0.000 title abstract 2
- 108090000790 Enzymes Proteins 0.000 title 1
- 102000004190 Enzymes Human genes 0.000 title 1
- 102100028255 Renin Human genes 0.000 title 1
- 108090000783 Renin Proteins 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 14
- 125000002947 alkylene group Chemical group 0.000 abstract 12
- 125000003545 alkoxy group Chemical group 0.000 abstract 10
- 125000001589 carboacyl group Chemical group 0.000 abstract 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 8
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 8
- 125000001072 heteroaryl group Chemical group 0.000 abstract 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 6
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 5
- 125000004414 alkyl thio group Chemical group 0.000 abstract 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 3
- 125000003302 alkenyloxy group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 125000005368 heteroarylthio group Chemical group 0.000 abstract 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
- -1 thiocarbamoyl Chemical group 0.000 abstract 2
- 125000005530 alkylenedioxy group Chemical group 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007858 starting material Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/11—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound oxygen atoms bound to the same saturated acyclic carbon skeleton
- C07C255/13—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound oxygen atoms bound to the same saturated acyclic carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/18—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyridine Compounds (AREA)
- Furan Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Pyrrole Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH116994 | 1994-04-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY2208B1 true CY2208B1 (en) | 2002-11-08 |
Family
ID=4204102
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY0000064A CY2208B1 (en) | 1994-04-18 | 2000-12-01 | Delta-amino-gamma-hydroxy-omega-aryl alkanoic acidamides with enzyme especially renin inhibiting ac tivities |
| CY200700027C CY2007027I2 (el) | 1994-04-18 | 2007-10-31 | ΑΜΙΔΙΑ δ-ΑΜΙΝΟ-γ-ΥΔΡΟΞΥ-ω-ΑΡΥΛΟ-ΑΛΚΑΝΙΚΟΥ ΟΞΕΟΣ ΜΕ ΙΔΙΟΤΗΤΕΣ ΑΝΑΣΤΟΛΗΣ ΕΝΖΥΜΩΝ, ΙΔΙΑΙΤΕΡΑ ΤΗΣ ΡΕΝΙΝΗΣ |
| CY2009006C CY2009006I1 (el) | 1994-04-18 | 2009-05-11 | ΑΜΙΔΙΑ δ-AMINO-γ-ΥΔΡΟΞΥ-ω-ΑΡΥΛΟ-ΑΛΚΑΝΙΚΟΥ ΟΞΕΟΣ ΜΕ ΙΔΙΟΤΗΤΕΣ ΑΝΑΣΤΟΛΗΣ ΕΝΖΥΜΩΝ, ΙΔΙΑΙΤΕΡΑ ΤΗΣ ΡΕΝΙΝΗΣ |
| CY2011015C CY2011015I2 (el) | 1994-04-18 | 2011-09-27 | ΑΜΙΔΙΑ δ-AMINO-γ-ΥΔΡΟΞΥ-ω-ΑΡΥΛΟ-ΑΛΚΑΝΙΚΟΥ ΟΞΕΟΣ ΜΕ ΙΔΙΟΤΗΤΕΣ ΑΝΑΣΤΟΛΗΣ ΕΝΖΥΜΩΝ, ΙΔΙΑΙΤΕΡΑ ΤΗΣ ΡΕΝΙΝΗΣ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY200700027C CY2007027I2 (el) | 1994-04-18 | 2007-10-31 | ΑΜΙΔΙΑ δ-ΑΜΙΝΟ-γ-ΥΔΡΟΞΥ-ω-ΑΡΥΛΟ-ΑΛΚΑΝΙΚΟΥ ΟΞΕΟΣ ΜΕ ΙΔΙΟΤΗΤΕΣ ΑΝΑΣΤΟΛΗΣ ΕΝΖΥΜΩΝ, ΙΔΙΑΙΤΕΡΑ ΤΗΣ ΡΕΝΙΝΗΣ |
| CY2009006C CY2009006I1 (el) | 1994-04-18 | 2009-05-11 | ΑΜΙΔΙΑ δ-AMINO-γ-ΥΔΡΟΞΥ-ω-ΑΡΥΛΟ-ΑΛΚΑΝΙΚΟΥ ΟΞΕΟΣ ΜΕ ΙΔΙΟΤΗΤΕΣ ΑΝΑΣΤΟΛΗΣ ΕΝΖΥΜΩΝ, ΙΔΙΑΙΤΕΡΑ ΤΗΣ ΡΕΝΙΝΗΣ |
| CY2011015C CY2011015I2 (el) | 1994-04-18 | 2011-09-27 | ΑΜΙΔΙΑ δ-AMINO-γ-ΥΔΡΟΞΥ-ω-ΑΡΥΛΟ-ΑΛΚΑΝΙΚΟΥ ΟΞΕΟΣ ΜΕ ΙΔΙΟΤΗΤΕΣ ΑΝΑΣΤΟΛΗΣ ΕΝΖΥΜΩΝ, ΙΔΙΑΙΤΕΡΑ ΤΗΣ ΡΕΝΙΝΗΣ |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US5559111A (cs) |
| EP (1) | EP0678503B1 (cs) |
| JP (1) | JP3240322B2 (cs) |
| KR (1) | KR100353779B1 (cs) |
| CN (2) | CN1266118C (cs) |
| AT (1) | ATE183997T1 (cs) |
| AU (1) | AU699616B2 (cs) |
| BR (1) | BR1100656A (cs) |
| CA (1) | CA2147056C (cs) |
| CY (4) | CY2208B1 (cs) |
| CZ (1) | CZ287935B6 (cs) |
| DE (4) | DE122009000020I1 (cs) |
| DK (1) | DK0678503T3 (cs) |
| ES (1) | ES2137478T3 (cs) |
| FI (1) | FI118336B (cs) |
| GR (1) | GR3031997T3 (cs) |
| HU (2) | HUT71701A (cs) |
| IL (1) | IL113403A (cs) |
| LU (2) | LU91373I2 (cs) |
| MY (1) | MY119161A (cs) |
| NL (2) | NL300296I2 (cs) |
| NO (4) | NO310410B1 (cs) |
| NZ (1) | NZ270936A (cs) |
| RU (1) | RU95105970A (cs) |
| TW (2) | TW366341B (cs) |
| ZA (3) | ZA953051B (cs) |
Families Citing this family (153)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4408534A1 (de) * | 1994-03-14 | 1995-09-28 | Hoechst Ag | Substituierte N-Ethyl-Glycinderivate zur Herstellung von PNA und PNA-/DNA-Hybriden |
| MY119161A (en) * | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
| EP0716077A1 (de) * | 1994-12-08 | 1996-06-12 | Ciba-Geigy Ag | Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren |
| US6465650B1 (en) | 1995-03-13 | 2002-10-15 | Aventis Pharma Deutschland Gmbh | Substituted N-ethylglycine derivatives for preparing PNA and PNA/DNA hybrids |
| HUP0100472A3 (en) * | 1997-12-16 | 2003-03-28 | Warner Lambert Co | Novel amines as pharmaceutical agents |
| US6846799B1 (en) | 1998-08-18 | 2005-01-25 | The Regents Of The University Of California | Preventing airway mucus production by administration of EGF-R antagonists |
| US7354894B2 (en) * | 1998-08-18 | 2008-04-08 | The Regents Of The University Of California | Preventing airway mucus production by administration of EGF-R antagonists |
| US6833460B2 (en) * | 1999-06-18 | 2004-12-21 | E. I. Du Pont De Nemours And Company | Preparation and use of gamma-butyrolactones as cross-linking agents |
| US6423850B1 (en) | 1999-06-18 | 2002-07-23 | E.I. Du Pont De Nemours And Company | Preparation and use of gamma-butyrolactones as cross-linking agents |
| EP1200384B1 (de) * | 1999-07-29 | 2004-04-28 | Speedel Pharma AG | 2-alkyl-5-halogen-pent-4-encarbonsäuren und deren herstellung |
| AU2001273762A1 (en) * | 2000-07-03 | 2002-01-14 | Speedel Pharma Ag | Process for the preparation of (r)-2-alkyl-3-phenyl-1-propanols |
| CN100482636C (zh) | 2000-07-05 | 2009-04-29 | 斯皮德尔药品公司 | 取代的辛酰胺的制备方法 |
| TR200401871T4 (tr) * | 2000-07-25 | 2004-08-23 | Speedel Pharma Ag | Değiştirilen oktanoil amitlerin (octanoyl amides) hazırlanması |
| US8168616B1 (en) * | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
| DE60123911T2 (de) | 2000-12-14 | 2007-05-31 | Speedel Pharma Ag | Verfahren zur Herstellung von Aryloctanoyl-amiden |
| JP3440082B2 (ja) | 2001-02-19 | 2003-08-25 | 科学技術振興事業団 | 電気自動車用インホイールモーター |
| DE60235374D1 (de) | 2001-05-15 | 2010-04-01 | Novartis Ag | Verfahren zur herstellung von substituierten carbonsäureestern mittels enzymatischer hydrolyse |
| WO2002100820A1 (en) * | 2001-06-11 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Substituted aminoalcohols useful in treatment of alzheimer's disease |
| CN1571668A (zh) * | 2001-10-18 | 2005-01-26 | 诺瓦提斯公司 | At1－受体拮抗剂和心血管药物形成的盐 |
| US20050101638A1 (en) * | 2002-11-08 | 2005-05-12 | Webb Randy L. | Combination of organic compounds |
| CN1655819A (zh) * | 2002-05-17 | 2005-08-17 | 诺瓦提斯公司 | 包含肾素抑制剂、钙通道阻断剂和利尿药的药物组合物 |
| GB0212410D0 (en) * | 2002-05-29 | 2002-07-10 | Novartis Ag | Organic compounds |
| AU2003237546A1 (en) * | 2002-06-11 | 2003-12-22 | Elan Pharmaceuticals, Inc. | METHODS OF TREATING ALZHEIMER'S DISEASE USING AROMATICALLY SUBSTITUTED Omega-AMINO-ALKANOIC ACID AMIDES AND ALKANOIC ACID DIAMIDES |
| US20060154926A1 (en) * | 2002-06-11 | 2006-07-13 | Elan Pharmaceuticals, Inc. | Methods of treating alzheimer's disease using aryl alkanoic acid amides |
| AU2003288899B2 (en) * | 2002-08-23 | 2009-09-03 | Novartis Vaccines And Diagnostics, Inc. | Benzimidazole quinolinones and uses thereof |
| US7049469B2 (en) | 2002-10-24 | 2006-05-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Process for preparing (R)-salbutamol |
| AU2003293155A1 (en) * | 2002-11-27 | 2004-06-23 | Elan Pharmaceutical, Inc. | Substituted ureas and carbamates |
| WO2004100871A2 (en) * | 2003-05-09 | 2004-11-25 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and a renin inhibitor |
| MXPA06002188A (es) * | 2003-08-25 | 2006-04-27 | Warner Lambert Co | Nuevos compuestos antimicrobianos de ariloxazolidinona. |
| CN102260188A (zh) | 2003-11-26 | 2011-11-30 | 诺瓦提斯公司 | 有机化合物 |
| GB0327839D0 (en) * | 2003-12-01 | 2003-12-31 | Novartis Ag | Organic compounds |
| PE20050596A1 (es) * | 2003-12-19 | 2005-10-18 | Novartis Ag | Microemulsion que comprende un inhibidor renina |
| JP2007518768A (ja) * | 2004-01-22 | 2007-07-12 | ノバルティス アクチエンゲゼルシャフト | 有機化合物の組み合わせ物 |
| PL1756037T3 (pl) * | 2004-01-23 | 2011-05-31 | Novartis Ag | Pochodne aminoalkoholi i ich aktywność jako inhibitory reniny |
| AR047447A1 (es) * | 2004-01-23 | 2006-01-18 | Speedel Experimenta Ag | Compuestos derivados de amino alcohol con actividad inhibidora de la renina y su uso en composiciones farmaceuticas. |
| WO2005089731A2 (en) | 2004-03-17 | 2005-09-29 | Novartis Ag | Use of renin inhibitors in therapy |
| US20070191487A1 (en) * | 2004-03-17 | 2007-08-16 | Rigassi-Dietrich Petra G | Galenic formulations of organic compounds |
| PE20110121A1 (es) * | 2004-03-17 | 2011-02-28 | Novartis Ag | Composiciones farmaceuticas de aliskiren |
| EP1725530A1 (en) * | 2004-03-19 | 2006-11-29 | Speedel Experimenta AG | Organic compounds |
| EP1724259A1 (en) * | 2004-03-19 | 2006-11-22 | Speedel Experimenta AG | 2,7-substituted 5-amino-4-hydroxy-8-(1h-indazol-5-yl)-octan amide derivatives and related compounds as renin inhibitors for the treatment of hypertension |
| WO2005095876A1 (en) | 2004-04-01 | 2005-10-13 | Cucumber Limited | Delivery and storage of goods |
| AR050043A1 (es) * | 2004-08-03 | 2006-09-20 | Novartis Ag | Metodos para mejorar la biodisponibilidad y composicion farmaceutica para trastornos cardiovasculares |
| GB0419361D0 (en) | 2004-08-31 | 2004-10-06 | Novartis Ag | Organic compounds |
| ATE551052T1 (de) | 2004-10-08 | 2012-04-15 | Novartis Ag | Verwendung von reninhemmern zur prävention oder behandlung von diastolischer dysfunktion oder diastolischer herzinsuffizienz |
| TW200633983A (en) * | 2004-12-10 | 2006-10-01 | Speedel Experimenta Ag | 5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-nonanamides |
| TW200631929A (en) * | 2004-12-10 | 2006-09-16 | Speedel Experimenta Ag | ω -phenyloctanamides |
| WO2006083924A1 (en) * | 2005-02-02 | 2006-08-10 | Vitae Pharmaceuticals, Inc. | 1-acylamino-2-hydroxy-3-amino-w-arylalkanes as renin inhibitors |
| CN101171230A (zh) * | 2005-03-11 | 2008-04-30 | 斯皮德尔实验股份公司 | 用作肾素抑制剂的杂环取代的链烷酰胺 |
| WO2006095020A1 (en) * | 2005-03-11 | 2006-09-14 | Speedel Experimenta Ag | Heterocyclic-substituted alkanamides useful as renin inhibitors |
| JP4763771B2 (ja) * | 2005-03-17 | 2011-08-31 | ビーエーエスエフ ソシエタス・ヨーロピア | 光学活性３−フェニルプロピオン酸誘導体を生成する方法、およびその誘導体の後続生成物 |
| GB0511686D0 (en) * | 2005-06-08 | 2005-07-13 | Novartis Ag | Organic compounds |
| EP1904469B1 (en) * | 2005-07-11 | 2011-09-21 | Novartis AG | New pyrocatechin derivatives |
| EP1745778A3 (en) | 2005-07-20 | 2007-03-07 | Speedel Experimenta AG | Diaminoalcohols as therapeutic compounds |
| AU2006272348B2 (en) | 2005-07-22 | 2011-06-16 | Merck Frosst Canada Ltd | Renin inhibitors |
| ES2328630T3 (es) * | 2005-09-17 | 2009-11-16 | Novartis Ag | Derivados de 5-amino-4-hydroxi-7-(imidazo (1,2-a>)piridin-6- ilmetil-8-metil-nonamida y compuestos relacionados como inhibidores de la renina para el tratamiento de la hipertension. |
| WO2007031557A2 (en) * | 2005-09-17 | 2007-03-22 | Speedel Experimenta Ag | Alcanoic acid amides substituted by saturated o-heterocycles |
| EP1764098A1 (en) * | 2005-09-17 | 2007-03-21 | Speedel Experimenta AG | Diaminoalcohols derivatives for the treatment of Alzheimer, malaria, HIV |
| GB0519764D0 (en) | 2005-09-28 | 2005-11-09 | Novartis Ag | Organic compounds |
| GB0521083D0 (en) * | 2005-10-17 | 2005-11-23 | Novartis Ag | Organic compounds |
| CA2626568A1 (en) * | 2005-10-18 | 2007-04-26 | Nicox S.A. | Renin inhibitors nitroderivatives |
| RU2008119687A (ru) | 2005-10-21 | 2009-11-27 | Новартис АГ (CH) | Комбинации органических соединений |
| GB2431646A (en) * | 2005-10-25 | 2007-05-02 | Novartis Ag | Alternative synthesis of aryl-octanoyl amide compounds |
| GB2431642A (en) * | 2005-10-25 | 2007-05-02 | Novartis Ag | Alternative synthesis of aryl-octanoyl amide compounds |
| GB2431645A (en) * | 2005-10-25 | 2007-05-02 | Novartis Ag | Alternative synthesis of aryl-octanoyl amide compounds |
| GB2431649A (en) * | 2005-10-25 | 2007-05-02 | Novartis Ag | Alternative synthesis of aryl-octanoyl amide compounds |
| GB2431648A (en) * | 2005-10-25 | 2007-05-02 | Novartis Ag | Alternative synthesis of aryl-octanoyl amide compounds |
| DE102005052195A1 (de) * | 2005-10-28 | 2007-05-03 | Reuter Chemischer Apparatebau Kg | Verfahren zur Herstellung von chiralen Octensäurederivaten |
| TW200804241A (en) * | 2006-02-24 | 2008-01-16 | Novartis Ag | New salt |
| GB0605688D0 (en) * | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic compounds |
| WO2007120523A2 (en) * | 2006-03-31 | 2007-10-25 | Vitae Pharmaceuticals, Inc. | 6-(aminoalkyl)indazoles |
| WO2007123718A1 (en) * | 2006-03-31 | 2007-11-01 | Vitae Pharmaceuticals, Inc. | 1-HETEROCYCLYLAMINO-2-HYDROXY-3-AMINO-ω-ARYLALKANES |
| KR20080108515A (ko) * | 2006-04-03 | 2008-12-15 | 노파르티스 아게 | 고혈압의 치료를 위한 레닌 억제제 |
| BRPI0713116A2 (pt) | 2006-06-23 | 2012-10-16 | Daiichi Sankyo Co Ltd | composto, composição farmacêutica, uso do composto, e, método para tratar ou prevenir uma doença |
| GB0612540D0 (en) | 2006-06-23 | 2006-08-02 | Novartis Ag | Galenical formulations of organic compounds |
| TW200815324A (en) * | 2006-06-23 | 2008-04-01 | Daiichi Sankyo Co Ltd | Straight chain amine compound |
| CA2657258A1 (en) | 2006-07-20 | 2008-01-24 | Novartis Ag | Amino-piperidine derivatives as cetp inhibitors |
| EP1911762A1 (en) | 2006-10-04 | 2008-04-16 | Speedel Experimenta AG | Amino alcohols and their use as renin inhibitors |
| US8119841B2 (en) * | 2006-11-07 | 2012-02-21 | Novartis Ag | Crystalline forms of aliskiren hemifumarate |
| CN101528672A (zh) * | 2006-11-09 | 2009-09-09 | 诺瓦提斯公司 | 阿利吉仑乳清酸盐 |
| EP1938812A1 (en) * | 2006-12-22 | 2008-07-02 | Speedel Pharma AG | Pharmaceutical composition using aliskiren and avosentan |
| EP1958666A1 (en) | 2007-02-13 | 2008-08-20 | Speedel Experimenta AG | Heterocyclic-substituted alkanamides as therapeutic compounds |
| AR065792A1 (es) * | 2007-03-21 | 2009-07-01 | Speedel Experimenta Ag | Proceso para preparar (r o s) -5- (1 -azido-3-(6-metoxi-5-(3-metoxi-propoxi) -piridin-3-ilmetil) -4-metil- pentil) -3-alquil-dihidro-furan-2-ona |
| EP1972335A1 (en) * | 2007-03-23 | 2008-09-24 | Krka | Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof |
| NZ579792A (en) * | 2007-04-03 | 2012-03-30 | Novartis Ag | Processes for preparing lactone compounds |
| EP2173696A1 (en) * | 2007-07-11 | 2010-04-14 | DSM IP Assets B.V. | Preparation of a saturated aldehyde |
| US20090076062A1 (en) * | 2007-09-13 | 2009-03-19 | Juergen Klaus Maibaum | Organic Compounds |
| US20090082458A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched aliskiren |
| AU2008303504C1 (en) | 2007-09-28 | 2013-05-16 | Novartis Ag | Galenical formulations of Aliskiren |
| DE102007049039A1 (de) | 2007-10-11 | 2009-04-16 | Reuter Chemischer Apparatebau Kg | Verfahren zur Herstellung von 8-Hydrazino-8-Aryl-Octanoylderivaten und deren Verwendung |
| KR101564793B1 (ko) | 2007-11-05 | 2015-10-30 | 노파르티스 아게 | 고지질혈증 또는 동맥경화증과 같은 질환의 치료에 유용한 ｃｅｔｐ 억제제로서의 4-벤질아미노-1-카르복시아실-피페리딘 유도체 |
| BRPI0822652A2 (pt) | 2007-11-13 | 2015-06-23 | Teva Pharmáceutica Ind Ltd Petach Tirva 49131 | Fórmulas polimórficas de hemifumarato de alisquireno e processos para a sua preparação |
| EP2062874B1 (en) | 2007-11-20 | 2014-12-17 | KRKA, tovarna zdravil, d.d., Novo mesto | Process and intermediates for the preparation of aliskiren |
| JP5421282B2 (ja) | 2007-12-03 | 2014-02-19 | ノバルティス アーゲー | 高脂血症または動脈硬化症のような疾患の処置に有用なｃｅｔｐ阻害剤としての１，２−二置換−４−ベンジルアミノ−ピロリジン誘導体 |
| EP2075244A1 (en) | 2007-12-24 | 2009-07-01 | DSMIP Assets B.V. | New route to building block for making renin inhibitors |
| KR101164300B1 (ko) | 2008-02-22 | 2012-07-09 | 한올바이오파마주식회사 | 약제학적 제제 |
| WO2009125981A2 (ko) | 2008-04-10 | 2009-10-15 | 한올제약주식회사 | 약제학적 제제 |
| CN102036948A (zh) * | 2008-05-23 | 2011-04-27 | 特瓦制药工业有限公司 | 阿利吉仑单富马酸盐及其制备方法 |
| WO2009149344A2 (en) * | 2008-06-06 | 2009-12-10 | Teva Pharmaceutical Industries Ltd. | Solid states of aliskiren free base |
| EP2143425A1 (de) | 2008-07-11 | 2010-01-13 | Ratiopharm GmbH | Direktverpresste Aliskiren-Tabletten |
| WO2010024772A1 (en) * | 2008-08-29 | 2010-03-04 | Medivir Ab | Aspartyl protease inhibitors |
| EP2163245A1 (en) | 2008-09-10 | 2010-03-17 | Novartis Ag | Renin inhibitors for the treatment of psoriasis |
| SI2189442T1 (sl) | 2008-11-20 | 2015-03-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Postopek in intermediati za pripravo aliskirena |
| MA33060B1 (fr) | 2009-01-28 | 2012-02-01 | Novartis Ag | Formulations galéniques de composés organiques |
| WO2010089105A2 (en) | 2009-02-05 | 2010-08-12 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Moisture-activated granulation process |
| CA2724152A1 (en) | 2009-02-05 | 2010-08-12 | Teva Pharmaceutical Industries Ltd. | Solid state forms of aliskiren compounds |
| US20120009257A1 (en) | 2009-03-20 | 2012-01-12 | Indrajit Ghosh | Galenical Formulations of a Fixed Dose Combination of Valsartan and Aliskiren |
| KR20110129482A (ko) | 2009-03-20 | 2011-12-01 | 노파르티스 아게 | 알리스키렌을 포함하는 제약 조성물 |
| WO2010112482A1 (en) | 2009-04-01 | 2010-10-07 | Lek Pharmaceuticals D.D. | A process for dimethylation of active methylene groups |
| CN102686556A (zh) * | 2009-08-11 | 2012-09-19 | 诺瓦提斯公司 | 内酯和内酰胺的开环 |
| US20120220663A1 (en) | 2009-09-03 | 2012-08-30 | Teva Pharmaceuticals Usa, Inc. | Solid forms of aliskiren hemifumarate and processes for preparation thereof |
| UA108742C2 (uk) | 2009-09-23 | 2015-06-10 | Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1 | |
| WO2011048523A1 (en) * | 2009-10-21 | 2011-04-28 | CarboDesign LLC | Process for the manufacture of enantiomerically pure aryloctanoic acids as aliskiren |
| WO2011051853A1 (en) * | 2009-10-29 | 2011-05-05 | CarboDesign LLC | Manufacturing process for preparing enaniomerically pure 8- aryloctanoic acid derivatives such as aliskiren |
| JP2013510145A (ja) * | 2009-11-09 | 2013-03-21 | メディヴィル・アクチエボラーグ | １，３−オキサゾリジン化合物およびレニン阻害剤としてのそれらの使用方法 |
| US20110113995A1 (en) * | 2009-11-13 | 2011-05-19 | Lindsay Corporation | Method and apparatus for planting and irrigation |
| US20110137047A1 (en) * | 2009-12-07 | 2011-06-09 | CarboDesign LLC | Process for enantiomerically pure 8-Aryloctanoic acids as Aliskiren |
| CA2783699C (en) | 2009-12-08 | 2019-01-15 | Case Western Reserve University | Primary amine compounds for treating ocular disorders |
| CN101774986B (zh) | 2010-01-06 | 2012-03-28 | 浙江天宇药业股份有限公司 | 一种制备阿利克伦及其中间体的方法 |
| CN102140068B (zh) * | 2010-01-30 | 2015-03-11 | 浙江华海药业股份有限公司 | 阿利吉仑中间体3-氨基-2,2-二甲基丙酰胺的制备方法 |
| EP2523934A1 (en) * | 2010-02-10 | 2012-11-21 | Ratiopharm GmbH | Salts of aliskiren |
| TW201136582A (en) | 2010-03-16 | 2011-11-01 | Novartis Ag | Improved pharmaceutical compositions of aliskiren and methods of delivery |
| TR201002256A1 (tr) * | 2010-03-24 | 2011-10-21 | Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� | Stabil aliskiren formülasyonları |
| EP2382967A1 (de) | 2010-04-21 | 2011-11-02 | ratiopharm GmbH | Aliskiren in Form einer festen Dispersion |
| US20110268797A1 (en) | 2010-04-30 | 2011-11-03 | Sanovel IIac Sanayi Ve Ticaret Anonim Sirketi | Multicoated aliskiren formulations |
| CN102241650B (zh) * | 2010-05-14 | 2014-05-07 | 浙江九洲药业股份有限公司 | 用于制备阿立克仑的中间体化合物及相关制备方法 |
| IT1402925B1 (it) * | 2010-12-10 | 2013-09-27 | Chemo Iberica Sa | Processo per la produzione di aliskiren |
| TW201202178A (en) | 2010-06-04 | 2012-01-16 | Chemo Iberica Sa | Process for producing Aliskiren |
| IT1400961B1 (it) * | 2010-06-04 | 2013-07-05 | Chemo Iberica Sa | Processo per la produzione di aliskiren |
| CN101913998A (zh) * | 2010-07-06 | 2010-12-15 | 上海朴颐化学科技有限公司 | 4-溴-2-(3-甲氧基丙氧基)-苯甲醚的制备方法 |
| WO2012034065A1 (en) | 2010-09-09 | 2012-03-15 | Teva Pharmaceutical Industries Ltd. | Aliskiren intermediates and a process for analyzing the purity of aliskiren |
| PL2630118T3 (pl) | 2010-10-19 | 2015-04-30 | Mylan Laboratories Ltd | Synteza Aliskirenu |
| CN102001920B (zh) | 2010-11-09 | 2013-05-15 | 常州制药厂有限公司 | 一种药物中间体的制备方法 |
| CN102161627A (zh) * | 2011-02-24 | 2011-08-24 | 中国药科大学 | ω-(N取代-氨基烷基)辛酰胺 |
| EP2551260A1 (en) | 2011-07-28 | 2013-01-30 | Chemo Ibérica, S.A. | Chemical process for opening ring compounds |
| CN102942477B (zh) * | 2011-08-14 | 2015-12-02 | 浙江华海药业股份有限公司 | 辛烯酸衍生物及其制备方法 |
| CN102351734B (zh) * | 2011-09-05 | 2014-02-26 | 浙江普洛医药科技有限公司 | 一种阿利克仑的制备方法 |
| WO2013045505A1 (en) | 2011-09-28 | 2013-04-04 | Novartis Ag | Biomarkers for raas combination therapy |
| US8703976B2 (en) * | 2011-10-02 | 2014-04-22 | Milan Soukup | Manufacturing process for 8-aryloctanoic acids such as Aliskiren |
| WO2013061224A1 (en) | 2011-10-25 | 2013-05-02 | Jubilant Life Sciences Limited | Process for the preparation of aliskiren |
| WO2013118138A1 (en) | 2011-12-13 | 2013-08-15 | Laboratories Ltd Mylan | Novel process for the preparation of renin inhibitors |
| CN103172533B (zh) * | 2011-12-20 | 2016-05-04 | 博瑞生物医药（苏州）股份有限公司 | 一种阿利克仑半富马酸盐的新晶型及其制备方法和用途 |
| CN103204834A (zh) * | 2012-01-11 | 2013-07-17 | 南京欧信医药技术有限公司 | 阿利克伦中间体及其制备方法和应用 |
| WO2013121443A1 (en) | 2012-02-17 | 2013-08-22 | Mylan Laboratories Ltd. | An improved process for the preparation of aliskiren |
| WO2013124868A2 (en) | 2012-02-21 | 2013-08-29 | Mylan Laboratories Limited | Solid form of aliskiren intermediate |
| ITMI20120354A1 (it) * | 2012-03-07 | 2013-09-08 | Friulchem Spa | Processo per la produzione di aliskirene |
| WO2013144979A1 (en) | 2012-03-28 | 2013-10-03 | Maylan Laboratories Ltd | Process for the preparation of aliskiren |
| CA2873869A1 (en) | 2012-05-11 | 2013-11-14 | Novartis Ag | Dispensing device |
| WO2013171767A1 (en) | 2012-05-18 | 2013-11-21 | Mylan Laboratories Limited | An improved process for the preparation of aliskiren |
| EP2810644A1 (en) | 2013-06-06 | 2014-12-10 | Ferrer Internacional, S.A. | Oral formulation for the treatment of cardiovascular diseases |
| CN105377858B (zh) * | 2013-06-27 | 2017-11-21 | 帕西昂奥地利有限两合公司 | 利用流化床制备格氏试剂 |
| US11081240B2 (en) | 2018-06-14 | 2021-08-03 | Astrazeneca Uk Limited | Methods for treatment of hypertension with an angiotensin II receptor blocker pharmaceutical composition |
| CN112679448B (zh) * | 2020-12-31 | 2022-08-19 | 苏州昊帆生物股份有限公司 | N-(2-氨基乙基)吗啉的制备方法 |
| CN115340472B (zh) * | 2022-09-19 | 2024-05-07 | 合肥工业大学 | 一种谷氨酸衍生物及其合成方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4337207A (en) * | 1980-09-04 | 1982-06-29 | Regents Of The University Of California | Biologically active catecholamine derivatives |
| US4729985A (en) * | 1985-08-09 | 1988-03-08 | Pfizer Inc. | Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues |
| JPH02124884A (ja) * | 1988-07-08 | 1990-05-14 | Zhongguo Yixuekexueyuan Yaowo Yanjiusuo | Ｎ―置換アミド誘導体 |
| MY119161A (en) * | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
-
1995
- 1995-03-30 MY MYPI95000816A patent/MY119161A/en unknown
- 1995-04-04 US US08/416,242 patent/US5559111A/en not_active Expired - Lifetime
- 1995-04-07 EP EP95810236A patent/EP0678503B1/de not_active Expired - Lifetime
- 1995-04-07 ES ES95810236T patent/ES2137478T3/es not_active Expired - Lifetime
- 1995-04-07 DE DE122009000020C patent/DE122009000020I1/de active Pending
- 1995-04-07 DE DE59506707T patent/DE59506707D1/de not_active Expired - Lifetime
- 1995-04-07 DE DE122007000071C patent/DE122007000071I2/de active Active
- 1995-04-07 AT AT95810236T patent/ATE183997T1/de active
- 1995-04-07 DK DK95810236T patent/DK0678503T3/da not_active Application Discontinuation
- 1995-04-10 TW TW084103730A patent/TW366341B/zh active
- 1995-04-12 NO NO19951441A patent/NO310410B1/no not_active IP Right Cessation
- 1995-04-12 FI FI951771A patent/FI118336B/fi not_active IP Right Cessation
- 1995-04-12 AU AU16421/95A patent/AU699616B2/en not_active Ceased
- 1995-04-13 ZA ZA953051A patent/ZA953051B/xx unknown
- 1995-04-13 RU RU95105970/04A patent/RU95105970A/ru unknown
- 1995-04-13 ZA ZA953052A patent/ZA953052B/xx unknown
- 1995-04-13 CA CA002147056A patent/CA2147056C/en not_active Expired - Lifetime
- 1995-04-13 ZA ZA953050A patent/ZA953050B/xx unknown
- 1995-04-13 NZ NZ270936A patent/NZ270936A/en not_active IP Right Cessation
- 1995-04-14 HU HU9501078A patent/HUT71701A/hu unknown
- 1995-04-14 CZ CZ1995976A patent/CZ287935B6/cs not_active IP Right Cessation
- 1995-04-14 HU HU9501076A patent/HU226860B1/hu active Protection Beyond IP Right Term
- 1995-04-15 TW TW084103732A patent/TW402582B/zh not_active IP Right Cessation
- 1995-04-17 IL IL11340395A patent/IL113403A/en active Protection Beyond IP Right Term
- 1995-04-17 CN CNB2004100346824A patent/CN1266118C/zh not_active Expired - Lifetime
- 1995-04-17 CN CNB951050370A patent/CN1153759C/zh not_active Expired - Lifetime
- 1995-04-17 KR KR1019950008959A patent/KR100353779B1/ko not_active Expired - Lifetime
- 1995-04-18 JP JP09253295A patent/JP3240322B2/ja not_active Expired - Lifetime
-
1996
- 1996-07-02 US US08/674,555 patent/US5654445A/en not_active Expired - Lifetime
- 1996-07-25 US US08/687,878 patent/US5627182A/en not_active Expired - Lifetime
- 1996-07-25 US US08/687,277 patent/US5646143A/en not_active Expired - Lifetime
-
1997
- 1997-02-14 US US08/800,671 patent/US5705658A/en not_active Expired - Lifetime
- 1997-05-07 BR BR1100656-0A patent/BR1100656A/pt active IP Right Grant
-
1999
- 1999-11-30 GR GR990403090T patent/GR3031997T3/el unknown
-
2000
- 2000-12-01 CY CY0000064A patent/CY2208B1/xx unknown
-
2007
- 2007-09-26 NL NL300296C patent/NL300296I2/nl unknown
- 2007-10-31 CY CY200700027C patent/CY2007027I2/el unknown
- 2007-10-31 LU LU91373C patent/LU91373I2/fr unknown
- 2007-10-31 NO NO2007011C patent/NO2007011I1/no unknown
-
2009
- 2009-04-24 NL NL300386C patent/NL300386I1/nl unknown
- 2009-05-06 LU LU91564C patent/LU91564I2/fr unknown
- 2009-05-11 CY CY2009006C patent/CY2009006I1/el unknown
- 2009-05-18 NO NO2009011C patent/NO2009011I2/no unknown
-
2011
- 2011-09-20 NO NO2011020C patent/NO2011020I1/no unknown
- 2011-09-27 CY CY2011015C patent/CY2011015I2/el unknown
- 2011-09-28 DE DE201112100052 patent/DE122011100052I1/de active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2208B1 (en) | Delta-amino-gamma-hydroxy-omega-aryl alkanoic acidamides with enzyme especially renin inhibiting ac tivities | |
| IL119750A0 (en) | Novel 7-(substituted) -8- (substituted) -9- (substituted amino) -6- demethyl -6- deoxytetracycline intermediates | |
| AR017111A1 (es) | Composiciones detergentes para el lavado de ropa con polimeros a base de aminas lineales para proporcionar beneficios en cuanto a aspecto exterior eintegridad a las telas lavadas con las mismas | |
| ES2108520T3 (es) | Di(met)acrilatos con grupos carbonato ciclicos. | |
| EP0403062A3 (en) | Tickened acidic liquid composition with amine fwa useful as a bleaching agent vehicle | |
| ES2000320A6 (es) | Procedimiento para la preparacion de compuestos de 1-oxa-3-oxo-4,8-diaza-espiro (4,5) decano | |
| FI973894A0 (fi) | 9-substituoidut porfyseenit | |
| AUPP109097A0 (en) | Napthalene derivatives | |
| DK0953563T3 (da) | Fremgangsmåde til fremstilling af depsipeptidderivater samt hidtil ukendte intermediater derfor | |
| EP0856509A3 (de) | Verfahren zur Herstellung von Diacylimiden | |
| FR2632637B1 (fr) | Ethers de la 2-amino-7-hydroxytetraline |